Beam Therapeutics (MEX:BEAM) Total Stockholders Equity: MXN20,998 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
67 GF Score
Price MXN436.81
GF Value MXN465.58
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Total Stockholders Equity?

Beam Therapeutics MEX:BEAM 67 Total Stockholders Equity is MXN20,998 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 67/100 and a GF Value™ of MXN465.58 (Fairly Valued). The stock has 4 warning signs investors should review.

Beam Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was MXN20,998 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Beam Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 was MXN204.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Beam Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.22.

Beam Therapeutics  (MEX:BEAM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Beam Therapeutics's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(20997.961-0)/102.742
=204.38

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Beam Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(266.541 + 4256.457) / 20997.961
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Total Stockholders Equity Related Terms

Beam Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Total Stockholders Equity Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 16,959.70 14,299.81 16,657.32 15,298.59 22,297.50

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,977.34 19,710.65 17,720.53 22,297.50 20,997.96
MEX:BEAM
67GF Score
Beam Therapeutics Inc MEX:BEAM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of MXN20,998 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Total Stockholders Equity of MXN20,998 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Beam Therapeutics and its competitors.
Is Beam Therapeutics' Total Stockholders Equity too high?
Beam Therapeutics' current Total Stockholders Equity is MXN20,998 Mil. Overall, Beam Therapeutics has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Total Stockholders Equity compare to KOD and TARS?
Beam Therapeutics' Total Stockholders Equity of MXN20,998 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Beam Therapeutics and its competitors. Beam Therapeutics's current Total Stockholders Equity is MXN20,998 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN465.58, compared to a current price of MXN436.81 — trading 6.2% below its estimated fair value. The current Total Stockholders Equity is MXN20,998 Mil. Beam Therapeutics' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Total Stockholders Equity is MXN20,998 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of MXN436.81 is trading 6.2% below its estimated GF Value™ of MXN465.58. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Total Stockholders Equity: MXN20,998 Mil
  • GF Value™: MXN465.58 vs. price of MXN436.81 (6.2% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
67GF Score

Get the complete analysis for MEX:BEAM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN436.81
Price
MXN465.58
GF Value